One should be aware that tumors classified in the past as GBM may carry an IDH1/IDH2 mutation or exhibit a G-CIMP phenotype (with or without an IDH1/IDH2 mutation), both of which are prognostic factors for longer survival in glioma patients [54]. This evidence concerns the gene IDH1 and central nervous system cancer.